Aytu BioPharma Statistics
Total Valuation
Aytu BioPharma has a market cap or net worth of $21.10 million. The enterprise value is $25.72 million.
Important Dates
The last earnings date was Wednesday, May 14, 2025, after market close.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Aytu BioPharma has 8.98 million shares outstanding. The number of shares has increased by 52.64% in one year.
| Current Share Class | 8.98M |
| Shares Outstanding | 8.98M |
| Shares Change (YoY) | +52.64% |
| Shares Change (QoQ) | -3.31% |
| Owned by Insiders (%) | 8.50% |
| Owned by Institutions (%) | 10.02% |
| Float | 6.66M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.17 |
| Forward PS | 1.07 |
| PB Ratio | 0.42 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 15.69 |
| EV / Sales | 0.31 |
| EV / EBITDA | 4.29 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.03, with a Debt / Equity ratio of 0.65.
| Current Ratio | 1.03 |
| Quick Ratio | 0.76 |
| Debt / Equity | 0.65 |
| Debt / EBITDA | 2.92 |
| Debt / FCF | n/a |
| Interest Coverage | -0.30 |
Financial Efficiency
Return on equity (ROE) is -3.06% and return on invested capital (ROIC) is -1.39%.
| Return on Equity (ROE) | -3.06% |
| Return on Assets (ROA) | -0.59% |
| Return on Invested Capital (ROIC) | -1.39% |
| Return on Capital Employed (ROCE) | -2.22% |
| Revenue Per Employee | $800,578 |
| Profits Per Employee | $16,069 |
| Employee Count | 102 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 2.37 |
Taxes
In the past 12 months, Aytu BioPharma has paid $467,000 in taxes.
| Income Tax | 467,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -16.49% in the last 52 weeks. The beta is 0.13, so Aytu BioPharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.13 |
| 52-Week Price Change | -16.49% |
| 50-Day Moving Average | 1.99 |
| 200-Day Moving Average | 1.66 |
| Relative Strength Index (RSI) | 60.54 |
| Average Volume (20 Days) | 193,576 |
Short Selling Information
The latest short interest is 492,409, so 5.49% of the outstanding shares have been sold short.
| Short Interest | 492,409 |
| Short Previous Month | 624,633 |
| Short % of Shares Out | 5.49% |
| Short % of Float | 7.39% |
| Short Ratio (days to cover) | 0.17 |
Income Statement
In the last 12 months, Aytu BioPharma had revenue of $81.66 million and earned $1.64 million in profits.
| Revenue | 81.66M |
| Gross Profit | 52.89M |
| Operating Income | -1.19M |
| Pretax Income | -12.61M |
| Net Income | 1.64M |
| EBITDA | 6.00M |
| EBIT | -1.19M |
| Earnings Per Share (EPS) | -$0.83 |
Full Income StatementBalance Sheet
The company has $18.17 million in cash and $22.52 million in debt, giving a net cash position of -$4.35 million or -$0.48 per share.
| Cash & Cash Equivalents | 18.17M |
| Total Debt | 22.52M |
| Net Cash | -4.35M |
| Net Cash Per Share | -$0.48 |
| Equity (Book Value) | 34.90M |
| Book Value Per Share | 5.66 |
| Working Capital | 1.81M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$5.53 million and capital expenditures -$211,000, giving a free cash flow of -$5.74 million.
| Operating Cash Flow | -5.53M |
| Capital Expenditures | -211,000 |
| Free Cash Flow | -5.74M |
| FCF Per Share | -$0.64 |
Full Cash Flow StatementMargins
Gross margin is 64.77%, with operating and profit margins of -1.45% and 2.01%.
| Gross Margin | 64.77% |
| Operating Margin | -1.45% |
| Pretax Margin | -0.66% |
| Profit Margin | 2.01% |
| EBITDA Margin | 7.35% |
| EBIT Margin | -1.45% |
| FCF Margin | n/a |
Dividends & Yields
Aytu BioPharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -52.64% |
| Shareholder Yield | -52.64% |
| Earnings Yield | 7.67% |
| FCF Yield | -26.86% |
Analyst Forecast
The average price target for Aytu BioPharma is $10.00, which is 325.53% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.00 |
| Price Target Difference | 325.53% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 9.69% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 6, 2023. It was a reverse split with a ratio of 0.05:1.
| Last Split Date | Jan 6, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.05:1 |
Scores
Aytu BioPharma has an Altman Z-Score of -2.8 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.8 |
| Piotroski F-Score | 3 |
